Diabetic patients are vulnerable to many vascular events. So, diabetic patients treated
with oral antidiabetic glibenclamide, may be also treated with oral anticoagulant warfarin, for
prophylaxis and treatment of atherothrombotic events. Aim of this study: was to evaluate the
possible drug-drug interaction between warfarin and glibenclamide in diabetic and
hypercoagulable rats. Material and methods: Fifty adult male albino rats (230-390 gm) were
enrolled and subgrouped into; I: control group; II: diabetic and hypercoagulable group; III: as
group II but treated with warfarin (0.07 mg/kg) orally for 5 consecutive days; Group IV: as
group III but treated with glibenclamide (0.6 mg/kg) orally for 5 consecutive days and group V:
as group IV but treated with both warfarin and glibenclamide. The following parameters were
then assessed; prothrombin time, activated partial thromboplastin time, clotting time, bleeding
time, serum glucose level and glycosylated hemoglobin. Results: The results showed that, PT,
aPTT, CT, BT were significantly (p < 0.001) prolonged while the serum glucose level was
significantly (p < 0.001) decreased and HbA1c was significantly (p < 0.01) decreased when
warfarin and glibenclamide were administered together more than when they were given alone.
Conclusion: A drug-drug interaction had occurred when warfarin and glibenclamide were
coadministered.